Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Steven Deitelzweig, Manuela Di Fusco, Amiee Kang, Mirko Savone, Ruth Mokgokong, Allison Keshishian, Cynthia Gutierrez & Joseph C. Cappelleri. (2021) Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Current Medical Research and Opinion 37:6, pages 891-902.
Read now
Read now
A. John Camm & Keith A. A. Fox. (2018) Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. Current Medical Research and Opinion 34:11, pages 1945-1957.
Read now
Read now
Emilio Márquez-Contreras, Nieves Martell-Claros, Sara Márquez-Rivero, Enrique Hermida-Campa, Carmen Gracia-Diez, Eugenio Sanchez-López & Vicente Gil-Guillén. (2018) Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study). Current Medical Research and Opinion 34:7, pages 1301-1308.
Read now
Read now
Walter Ageno, Jan Beyer-Westendorf & Andrea Rubboli. (2017) Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 18:13, pages 1325-1332.
Read now
Read now
Emilio Márquez-Contreras, Nieves Martell-Carlos, Vincente Gil-Guillén, Mariano De La Figuera-Von Wichmann, Eugenio Sanchez-López, Sara Márquez-Rivero, Ines Gil-Gil & Enrique Hermida-Campa. (2016) Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study. Current Medical Research and Opinion 32:12, pages 2013-2020.
Read now
Read now
Andrea Rubboli. (2015) Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter?. Current Medical Research and Opinion 31:10, pages 1845-1847.
Read now
Read now
András Komócsi. (2015) Discontinuation of anticoagulant treatment: from clinical trials to medication persistence. Current Medical Research and Opinion 31:10, pages 1841-1844.
Read now
Read now
Articles from other publishers (21)
Prachi Arora, Maria Muehrcke, Molly Russell & Saurabh Ghanekar. (2023) Utilization outcomes of direct oral anticoagulants in Medicare patients. Research in Social and Administrative Pharmacy.
Crossref
Crossref
Giuseppe Patti, Rosa Wang, Xiaocong Li Marston, Yu-Chen Yeh, Lisa Zimmermann, Xin Ye, Xin Gao & Bernd Brüggenjürgen. (2023) Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation. Cardiology and Therapy 12:2, pages 371-391.
Crossref
Crossref
Prachi Arora, Maria Muehrcke, Molly Russell & Rasitha Jayasekare. (2022) Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants. Journal of Comparative Effectiveness Research 11:15, pages 1105-1120.
Crossref
Crossref
Esa Y H Chen, Jiaxi Zhao, Jenni Ilomäki, Janet K Sluggett, J Simon Bell, Barbara C Wimmer, Sarah N Hilmer, Joseph E Blais, Ian C K Wong & Esther W Chan. (2022) Medication Regimen Complexity and Risk of Bleeding in People Who Initiate Oral Anticoagulants for Atrial Fibrillation: A Population-Based Study. The Journals of Gerontology: Series A.
Crossref
Crossref
Alessia Romagnoli, Fiorenzo Santoleri, Alberto Costantini & Angelora Di Risio. (2022) Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years. European Journal of Hospital Pharmacy, pages ejhpharm-2022-003338.
Crossref
Crossref
M. Sabaté, X. Vidal, E. Ballarin, M. Rottenkolber, S. Schmiedl, B. Grave, C. Huerta, E. Martin-Merino, D. Montero, L. M. Leon-Muñoz, C. Gasse, N. Moore, C. Droz, R. Lassalle, M. Aakjær, M. Andersen, M. L. De Bruin, P. Souverein, O. H. Klungel, H. Gardarsdottir & L. Ibáñez. (2021) Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015). Frontiers in Pharmacology 12.
Crossref
Crossref
Anouk J. W. Gulpen, Hugo ten Cate, Yvonne M. C. Henskens, René van Oerle, Rick Wetzels, Simon Schalla, Harry J. Crijns & Arina J. ten Cate-Hoek. (2019) The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. PLOS ONE 14:6, pages e0217302.
Crossref
Crossref
Joya D. Pickett. (2019) Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. Critical Care Nurse 39:2, pages 54-67.
Crossref
Crossref
Ameenathul M. Fawzy & Gregory Y.H. Lip. (2019) Anticoagulation in elderly patients with nonvalvular atrial fibrillation: A balancing act. Heart Rhythm 16:1, pages 38-40.
Crossref
Crossref
Jean Dallongeville, Frédéric Sacher, Stéphane Bouée, Corinne Emery, Isabelle Bureau, Julie Gourmelen & Laurent Fauchier. (2018) Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. Therapies 73:6, pages 449-460.
Crossref
Crossref
M. de la Figuera, M.A. Prieto, N. Marín, I. Egocheaga & S. Cinza. (2018) Diferencias en el manejo de los pacientes con fibrilación auricular según inicie el tratamiento con anticoagulantes orales de acción directa el médico de atención primaria o el especialista. Estudios SILVER-AP y BRONCE-AP. Medicina de Familia. SEMERGEN 44:5, pages 323-334.
Crossref
Crossref
Andreas Zirlik & Christoph Bode. (2016) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 43:3, pages 365-379.
Crossref
Crossref
Emilio Márquez-Contreras, Nieves Martell-Claros, Vicente Gil-Guillén, Mariano De la Figuera-Von Wichmann, Eugenio Sánchez-López, Ines Gil-Gil & Sara Márquez-Rivero. (2017) Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance. Quality of Life Research 26:3, pages 647-654.
Crossref
Crossref
Andreas Goette & Matthias Hammwöhner. (2016) How important it is for therapy adherence to be once a day?. European Heart Journal Supplements 18:suppl I, pages I7-I12.
Crossref
Crossref
Jan Beyer-Westendorf, Birgit Ehlken & Thomas Evers. (2016) Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 18:8, pages 1150-1157.
Crossref
Crossref
Dagmar Kubitza, Scott D. Berkowitz & Frank Misselwitz. (2016) Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clinical and Applied Thrombosis/Hemostasis 22:5, pages 412-422.
Crossref
Crossref
John K. Abdou, Vivian Auyeung, Jignesh P. Patel & Roopen Arya. (2016) Adherence to long-term anticoagulation treatment, what is known and what the future might hold. British Journal of Haematology 174:1, pages 30-42.
Crossref
Crossref
Craig I. Coleman, Muralikrishna Tangirala & Thomas Evers. (2016) Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States. PLOS ONE 11:6, pages e0157769.
Crossref
Crossref
Marek Jauß, Sibylle Kaiser & Christian Tanislav. (2016) Neue Einsichten durch Real-World-Daten zu oralen Non-Vitamin-K-Antikoagulanzien. InFo Neurologie & Psychiatrie 18:6, pages 46-60.
Crossref
Crossref
Alan D. Bell, Peter Gross, Michael Heffernan, Yan Deschaintre, Jean-Francois Roux, Daniel M. Purdham & Ashfaq Shuaib. (2016) Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation. The American Journal of Cardiology 117:7, pages 1107-1111.
Crossref
Crossref
Judith Hecker, Sandra Marten, Loretta Keller, Sindy Helmert, Franziska Michalski, Sebastian Werth, Kurtulus Sahin, Luise Tittl & Jan Beyer-Westendorf. (2017) Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Thrombosis and Haemostasis 115:05, pages 939-949.
Crossref
Crossref